Blue California has announced the completion of a human clinical trial on ergothioneine. A double-blinded placebo-controlled clinical trial sponsored by Blue California has shown that ErgoActive ergothioneine supports aspects of cognitive function, memory, and sleep in healthy elderly subjects with subjective memory complaints.
“Blue California is proud to have sponsored such an important human study,” said Linda May-Zhang, PhD, vice-president of science and innovation at Blue California. “We are pleased by the results showing improvements of cognitive function and ability to get to sleep in subjects consuming ErgoActive for four months.”
Research has suggested that inadequate levels of ergothioneine are associated with a range of health problems, including cardiovascular disease, frailty, age-related cognitive decline, neurodegenerative diseases such as Parkinson’s disease, and dementias such as Alzheimer’s disease. Mushroom consumption and estimated dietary ergothioneine intake have previously been associated with reduced risk of cognitive decline and potentially longer lifespan.
Despite decades of preclinical research, association studies, and clinical studies conducted with mushrooms, it remained untested whether supplementation with pure ergothioneine can improve cognitive outcomes. Rigorous clinical studies were lacking.
Sharing his insights, Robert B. Beelman, PhD, professor emeritus of food science and director of the centre for plant and mushroom foods for health at Pennsylvania State University, stated: “The results of this study provide important clinical evidence supporting the idea that ergothioneine is a ‘longevity vitamin’ that can help mitigate cognitive decline and sleep issues commonly associated with ageing.”